The 48 references in paper O. Pylaeva A., K. Mukhin Yu., О. Пылаева А., К. Мухин Ю. (2015) “Применение зонисамида (Зонегран) в лечении эпилепсии: акцент на монотерапию фокальных приступов (обзор зарубежной литературы) // USE OF ZONISAMIDE (ZONEGRAN) IN THE TREATMENT OF EPILEPSY: EMPHASIS ON MONOTHERAPY OF FOCAL SEIZURES (A REVIEW OF FOREIGN LITERATURE)” / spz:neicon:rjdn:y:2014:i:2:p:42-49

1
Пылаева О.А., Мухин К.Ю. Применение нового антиэпилептического препарата – зонегран (зонисамид) – в лечении эпилепсии (обзор литературы). Рус журн дет неврол 2012;7(2):13–34.
(check this in PDF content)
2
Afra P., Adamolekun B. Update on once-daily zonisamide monotherapy in partial seizures. Neuropsychiatr Dis Treat 2014;10:493–8.
(check this in PDF content)
3
Arzimanoglou A., Rahbani A. Zonisamide for the treatment of epilepsy. Expert Rev Neurother 2006;6(9):1283–92.
(check this in PDF content)
4
Baulac M. Introduction to zonisamide. Epilepsy Res 2006;68 Suppl 2:S3–9.
(check this in PDF content)
5
Baulac M., Brodie M.J., Patten A. et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012;11(7):579–88.
(check this in PDF content)
6
Baulac M., Leppik I.E. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007;75(2–3):75–83.
(check this in PDF content)
7
Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007;30(4):230–40.
(check this in PDF content)
8
Biton V. Zonisamide: newer antiepileptic agent with multiple mechanisms of action. Expert Rev Neurother 2004;4(6):935–43.
(check this in PDF content)
9
Brodie M.J. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res 2006;68 Suppl 2:S11–6.
(check this in PDF content)
10
Brodie M.J. Zonisamide clinical trials: European experience. Seizure 2004;13 Suppl 1: S66–70. 4848 RGDN_02_2014 Block.indd 48RGDN_02_2014 Block.indd 4830.05.2014 9:23:2530.05.2014 9:23:25
(check this in PDF content)
11
Brodie M.J., Duncan R., Vespignani H. et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46(1):31–41.
(check this in PDF content)
12
Chadwick D.W., Marson A.G. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002;(2):CD001416.
(check this in PDF content)
13
Elger C.E., Schmidt D. Modern management of epilepsy: а practical approach. Epilepsy Behavior 2008;12(4):501–39.
(check this in PDF content)
14
Farooq M.U., Moore P.W., Bhatt A. et al. Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem 2008;8(10):968–75.
(check this in PDF content)
15
Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 2004;13 Suppl 1:S59–65.
(check this in PDF content)
16
Frampton J.E., Scott L.J. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005;19(4):347–67.
(check this in PDF content)
17
Fujii T., Furukama H., Matsumoto K. et al. Dainippon Pharmaceutical Co, Ltd, Developmental Laboratories. Data on file, 1989. Japanese.
(check this in PDF content)
18
Fukushima K., Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia 2006;47(11):1860–4.
(check this in PDF content)
19
Gadde K.M., Franciscy D.M., Wagner H.R. 2nd, Krishnan K.R. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289(14):1820–5.
(check this in PDF content)
20
Glauser T., Ben-Menachem E., Bourgeois B. et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54(3):551–63.
(check this in PDF content)
21
Helmstaedter C., Stefan H., Witt J.A. Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective noninterventional surveillance study. Epileptic Disord 2011;13(3)263–76.
(check this in PDF content)
22
Janszky J. Role of zonisamide in treating epilepsy, Parkinson disorders and other neurological diseases. Ideggyogy Sz 2009;62(11–12):383–9.
(check this in PDF content)
23
Kelemen A., Rasonyl G., Neuwirth M. et al. Our clinical experience with zonisamide in resistant generalized epilepsy syndromes. Ideggyogy Sz 2011;64(5–6):187–92.
(check this in PDF content)
24
Kim H.L., Aldridge J., Rho J.M. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol 2005;20(3):212–19.
(check this in PDF content)
25
Kothare S.V., Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol 2008;4(4):493–506.
(check this in PDF content)
26
Kothare S.V., Kaleyias J., Mostofi N. et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatric Neurol 2006;34(5):351–4.
(check this in PDF content)
27
Kwak S.E., Kim J.E., Kim D.S. et al. Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil. Neuropeptides 2005;39(5):507–13.
(check this in PDF content)
28
Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314–9.
(check this in PDF content)
29
Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8.
(check this in PDF content)
30
Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406.
(check this in PDF content)
31
Leppik I.E. Practical prescribing and longterm efficacy and safety of zonisamide. Epilepsy Res 2006;68 Suppl 2:S17–24.
(check this in PDF content)
32
Leppik I.E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13 Suppl 1:S5–9.
(check this in PDF content)
33
Lu Y., Xiao Z., Yu W. et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebocontrolled trial. Clin Drug Investig 2011;31(4):221–9.
(check this in PDF content)
34
Newmark M.E., Dubinsky S. Zonisamide monotherapy in multi-group clinic. Seizure 2004;13(4):223–25.
(check this in PDF content)
35
Ohtahara S. Zonisamide in the management of epilepsy – Japanese experience. Epilepsy Res 2006;68 Suppl 2: S25–33.
(check this in PDF content)
36
Ohtahara S., Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 2004;13 Suppl 1:S50–5.
(check this in PDF content)
37
Park S.P., Kim S.Y., Hwang Y.H. et al. Long term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol 2007;3(4):175–80.
(check this in PDF content)
38
Seino M. Review of zonisamide development in Japan. Seizure 2004;13 Suppl 1: S2–4.
(check this in PDF content)
39
Seki T., Kumagai N., Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure 2004;13 Suppl 1:S26–32.
(check this in PDF content)
40
Sobieszek G., Borowicz K.K., Kimber-Trojnar Z. et al. Zonisamide: a new antiepileptic drug. Pol J Pharmacol 2003;55(5):683–9.
(check this in PDF content)
41
Tosches W.A., Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006;8(3):522–6.
(check this in PDF content)
42
Ueda Y., Doi T., Tokumaru J., Willmore L.J. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003;116(1–2):1–6.
(check this in PDF content)
43
Wilfong A.A. Zonisamide monotherapy for epilepsy in children and young adults. Pediatr Neurol 2005;32(2):77–80.
(check this in PDF content)
44
Wilfong A.A., Willmore L.J. Zonisamide – a review of experience and use in partial seizures. Neuropsychiatr Dis Treat 2006;2(3):269–80.
(check this in PDF content)
45
Yamauchi T., Aikawa H. Efficacy of zonisamide: our experience. Seizure 2004; 13 Suppl 1:S41–8.
(check this in PDF content)
46
Zaccara G., Specchio L.M. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat 2009;5:249–59.
(check this in PDF content)
47
Zaccara G., Tramacere L., Cincotta M. Drug safety evaluation of zonisamide for the treatment of epilepsy. Expert Opin Drug Saf 2011;10(4):623–31.
(check this in PDF content)
48
Zareba G. Zonisamide: review of its use in epilepsy therapy. Drugs Today (Barc) 2005;41(9):589–97. 4949 RGDN_02_2014 Block.indd 49RGDN_02_2014 Block.indd 4930.05.2014 9:23:2530.05.2014 9:23:25
(check this in PDF content)